In this article, we are going to take a look at where Akebia Therapeutics Inc. (NASDAQ:AKBA) stands against other Thursday’s worst-performing stocks. Wall Street’s main indices edged lower on ...

Akebia Therapeutics, Inc. AKBA is a biopharmaceutical company. that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum ...

Akebia Therapeutics, Inc.AKBA is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front. Recently ...

Akebia Therapeutics (NASDAQ:AKBA) announced Thursday that it has regained full rights to sell its newly approved kidney disease therapy Vafseo (vadadustat) in the U.S. after its partner CSL Vifor ...

The average one-year price target for Akebia Therapeutics (NASDAQ:AKBA) has been revised to 4.59 / share. This is an increase of 16.13% from the prior estimate of 3.95 dated October 31 ...